{"id":655285,"date":"2023-06-13T13:08:01","date_gmt":"2023-06-13T13:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655285"},"modified":"2023-06-13T13:08:01","modified_gmt":"2023-06-13T13:08:01","slug":"crohns-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-centocor-ortho-biotech-ucb-biopharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-centocor-ortho-biotech-ucb-biopharmaceuticals_655285.html","title":{"rendered":"Crohn&#8217;s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies &#8211; Centocor Ortho Biotech, UCB Biopharmaceuticals."},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Crohn&#039;s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Centocor Ortho Biotech, UCB Biopharmaceuticals.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Crohn&#039;s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Centocor Ortho Biotech, UCB Biopharmaceuticals.\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cCrohn&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn&#8217;s Disease market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Crohn&#8217;s Disease Pipeline Insights, 2023<\/a><\/strong>&#8221; report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn&#8217;s Disease market. A detailed picture of the Crohn&#8217;s Disease pipeline landscape is provided, which includes the disease overview and Crohn&#8217;s Disease treatment guidelines.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Crohn&#8217;s Disease Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Crohn&#8217;s Disease companies developing novel drug candidates are Centocor Ortho Biotech, UCB Biopharmaceuticals, and others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Crohn&#8217;s Disease pipeline therapies in various stages of development include Adalimumab,&nbsp; Infliximab, Certolizumab, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Crohn&#8217;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. It is a group of inflammatory conditions of the colon and small intestine. In IBD, the immune system responds incorrectly to environmental triggers, which causes inflammation of the gastrointestinal tract. The two major types of IBD are ulcerative colitis (UC), which is inflammation and sores (ulcers) along the superficial lining of the large intestine (colon) and rectum, and Crohn&rsquo;s disease (CD), which involves inflammation of the lining of the digestive tract and can often involve the deeper layers of the digestive tract. The&nbsp; CD is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but CD is most often diagnosed in adolescents and adults between the ages of 20 and 30. There are different types of CD, each affecting different parts of the digestive tract including ileocolitis, ileitis, gastroduodenal Crohn&rsquo;s disease, jejunoileitis, and Crohn&rsquo;s colitis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/cbe04d9c73f722626c4c04c48bdecfa4.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Discover more about the emerging Crohn&#8217;s Disease drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Crohn&#8217;s Disease Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Crohn&#8217;s Disease Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Centocor Ortho Biotech: Adalimumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">UCB Biopharmaceuticals: Infliximab<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And&nbsp; many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\" target=\"_blank\"><strong>Scope of the Crohn&#8217;s Disease Pipeline Report&nbsp;<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Crohn&#8217;s Disease&nbsp; Companies: Centocor Ortho Biotech, UCB Biopharmaceuticals, and others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Crohn&#8217;s Disease&nbsp; Pipeline Therapies: Adalimumab,&nbsp; Infliximab, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find out more about the Crohn&#8217;s Disease treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Crohn&#8217;s Disease Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crohns-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-centocor-ortho-biotech-ucb-biopharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crohns-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-centocor-ortho-biotech-ucb-biopharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cCrohn&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn&#8217;s Disease market. DelveInsight&rsquo;s &ldquo;Crohn&#8217;s Disease Pipeline Insights, 2023&#8221; report by DelveInsight outlines &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-centocor-ortho-biotech-ucb-biopharmaceuticals_655285.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-655285","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=655285"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655285\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=655285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=655285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=655285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}